<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042921</url>
  </required_header>
  <id_info>
    <org_study_id>CN-SMG-11774</org_study_id>
    <nct_id>NCT05042921</nct_id>
  </id_info>
  <brief_title>Pediatric SMA China Registry</brief_title>
  <official_title>Pediatric Patients With Spinal Muscular Atrophy in China: A Nationwide Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to describe the natural history and utilization of&#xD;
      disease modifying therapy (DMT) treatments among pediatric chinese participants with spinal&#xD;
      muscular atrophy linked to chromosome 5q (5q-SMA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>21 Months</target_duration>
  <primary_outcome>
    <measure>Natural History and Utilization of Disease Modifying Therapy (DMT) Treatments Among Pediatric Chinese Participants With Spinal Muscular Atrophy Linked to Chromosome 5q (5q-SMA)</measure>
    <time_frame>Up to 21 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Effectiveness of DMT Treatments</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>Effectiveness will be assessed using following measures: time to mortality, motor function, motor measures, pulmonary function, scoliosis, hospitalizations and comorbidities, clinical observations, patient reported outcomes, wheelchair use, nutrition and electrophysiology and biomarkers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety of DMT Treatments</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>Safety will be assessed by adverse events (AEs) and serious AEs.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>DMT Treated Participants</arm_group_label>
    <description>Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 21 months and the available data is collected retrospectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Participants</arm_group_label>
    <description>Participants with SMA who received no treatment will be followed prospectively for up to 21 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric participants with 5q-SMA will be enrolled to obtain information on both the&#xD;
        natural history of the disease and effectiveness and safety of DMTs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Ability of the participant and/or his/her legally authorized representative (e.g.,&#xD;
             parent or legal guardian), as appropriate and applicable, to understand the purpose&#xD;
             and risks of the study, to provide informed consent, and to authorize the use of&#xD;
             confidential health information in accordance with national and local privacy&#xD;
             regulations.&#xD;
&#xD;
          -  Genetically confirmed 5q-SMA.&#xD;
&#xD;
          -  Age &lt; 18 years at enrollment.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent.&#xD;
&#xD;
          -  Other types of SMA (non 5q-SMA).&#xD;
&#xD;
        NOTE: Other protocol defined inclusion/ exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

